Emerging Company Profile


<div class="articleContainer">
<div class="articleWrapper">
<div class="articleContent">
<h1 class="text title" doc-editable="text" data-component-id="doc-1ef7l320d0">Concarlo: targeting proliferation and resistance in one go</h1><h2 class="title-bottom" doc-editable="title" data-component-id="doc-1ef7l34r60">SUNY Downstate spinout takes aim at metastatic breast cancer&#xA0;by targeting p27</h2><div class="byline ng-tns-c17-4 ng-star-inserted" data-component-id="doc-1ef7l3fol0">
    <span class="ng-tns-c17-4" doc-editable="text">By Virginia Li, Associate Editor</span>
</div><div class="date">August 28, 2020 9:42 PM GMT</div></div></div></div>


Cancer

Breast cancer

Cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)

Concarlo: targeting proliferation and resistance in one go

By targeting p27, SUNY Downstate spinout Concarlo simultaneously takes aim at mechanisms of proliferation and resistance in cancer, starting with metastatic breast cancer. 

SUNY Downstate spinout takes aim at metastatic breast cancer by targeting p27

Featured Analysis

Articles

Current Editions

Data Graphics

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

Events

My Workspace

Company Overview

Management

Editorial & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home